Success Metrics

Completion Rate

0%(0/1)

Active Trials

2(67%)

Terminated

1(33%)

Phase Distribution

Ph phase_1

33%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

Phase 1Safety & dosage

1(50.0%)

Phase 2Efficacy & side effects

1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Terminated(1)

Detailed Status

Active, not recruiting1

Recruiting1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (50.0%)

Phase 21 (50.0%)

Trials by Status

active_not_recruiting133%

recruiting133%

terminated133%

Recent Activity

2 active trials

Showing 3 of 3

active_not_recruitingphase_1

A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations

NCT07597668

terminatedphase_2

Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis

NCT04925557

recruiting

Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI

NCT04448977

Clinical Trials (3)

Showing 3 of 3 trials

NCT07597668Phase 1

A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations

Active Not Recruiting

NCT04925557Phase 2

Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis

Terminated

NCT04448977

Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI

Recruiting

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3